Justin "Jay" Bader, MD
Hospital ResidentCards
About
Research
Publications
2026
Peritoneal Metastases in Stage II-III Colon Cancer Represent a Blind Spot for Circulating Tumor DNA Surveillance.
Ofori KA, Smart H, Liu S, Bader JM, Aguirre N, Gupta P, Sharma A, Turaga K. Peritoneal Metastases in Stage II-III Colon Cancer Represent a Blind Spot for Circulating Tumor DNA Surveillance. Ann Surg Oncol 2026 PMID: 42265516, DOI: 10.1245/s10434-026-19903-8.Peer-Reviewed Original ResearchCEACAM5 as a biomarker of semi-solid, lepidic lung adenocarcinoma
Bader, J. M., de Santis, W., Ermer, T., & Woodard, G. A. (2026). CEACAM5 as a biomarker of semi-solid, lepidic lung adenocarcinoma. Translational Lung Cancer Research, 15(5).Peer-Reviewed Original ResearchNatural History, Treatment, Survival, and Causes of Mortality in Patients With Subsolid and Ground-Glass Nodules
Justin M. Bader, Samantha R. Prince, William de Santis, Emma R. Kane, Lynn Tanoue, Anna S. Bader, Justin D. Blasberg, Frank C. Detterbeck, Gavitt A. Woodard, Natural History, Treatment, Survival, and Causes of Mortality in Patients With Subsolid and Ground-Glass Nodules, CHEST, 2026, ISSN 0012-3692Peer-Reviewed Original ResearchRadiographic tumor regression as a predictor for pathologic response after neoadjuvant therapy for non–small cell lung cancer
Bader JM, Ermer T, de Santis W, Ragoowansi H, Kramer RJ, Zolfaghari EJ, Tremblay EE, Resio BJ, Boffa DJ, Blasberg JD, Bader AS, Dacic S, Woodard GA. Radiographic tumor regression as a predictor for pathologic response after neoadjuvant therapy for non–small cell lung cancer. JTCVS Open 2026, 101831. DOI: 10.1016/j.xjon.2026.101831.Peer-Reviewed Original ResearchEvolving therapeutics in colorectal cancer peritoneal metastases
Bader J, Aguirre N, Schultz K, Ofori K, Godfrey E, Gupta P, Tseng R, Cecchini M, Sundar R, Turaga K. Evolving therapeutics in colorectal cancer peritoneal metastases. Cancer And Metastasis Reviews 2026, 45: 25. PMID: 42024175, DOI: 10.1007/s10555-026-10335-0.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsHyperthermic intraperitoneal chemotherapyColorectal cancer peritoneal metastasesCytoreductive surgeryPeritoneal metastasisClinical trialsLandmark clinical trialsIntraperitoneal chemotherapySystemic therapyCRC-PMTherapeutic challengeDiagnostic challengeGuideline recommendationsTherapeutic approachesTreatment approachesMetastasisTrialsChemotherapySurgeryTherapyASO Author Reflections: New Insights for Personalized HIPEC Strategies in Colorectal Cancer Peritoneal Metastases
Gupta P, Godfrey E, Schultz K, Qiao L, Aguirre N, Bader J, Foote M, Shen J, Shergill A, Cecchini M, Sundar R, Sheltzer J, Turaga K. ASO Author Reflections: New Insights for Personalized HIPEC Strategies in Colorectal Cancer Peritoneal Metastases. Annals Of Surgical Oncology 2026, 1-2. PMID: 41896510, DOI: 10.1245/s10434-026-19312-x.Peer-Reviewed Original ResearchPIK3CA Mutations in Early-Onset Appendiceal Adenocarcinoma
Gupta P, Gujarathi R, Qiao L, Godfrey E, Schultz K, Butensky S, Bader J, Sundar R, Cecchini M, Shergill A, Sheltzer J, Turaga K. PIK3CA Mutations in Early-Onset Appendiceal Adenocarcinoma. JCO Precision Oncology 2026, 10: e2500741. PMID: 41712872, DOI: 10.1200/po-25-00741.Peer-Reviewed Original ResearchThis study investigates PIK3CA mutations in early-onset appendiceal adenocarcinoma, showing their higher prevalence and association with worse survival, suggesting potential for targeted therapies.Consensus Molecular Subtypes Inform HIPEC Agent Selection in Colorectal Cancer Peritoneal Metastases
Gupta P, Godfrey E, Schultz K, Qiao L, Aguirre N, Bader J, Foote M, Shen J, Shergill A, Cecchini M, Sundar R, Sheltzer J, Turaga K. Consensus Molecular Subtypes Inform HIPEC Agent Selection in Colorectal Cancer Peritoneal Metastases. Annals Of Surgical Oncology 2026, 1-6. PMID: 41634518, DOI: 10.1245/s10434-025-19057-z.Peer-Reviewed Original ResearchThis study investigates drug sensitivity in colorectal cancer peritoneal metastases, showing CMS4 tumors respond better to mitomycin-C and irinotecan, informing personalized chemotherapy strategies.Deep learning approach for critical exposure during division of the inferior mesenteric artery in colorectal surgery
Bader J, Sun X, Rosenfelt T, Ramirez-Hardy A, Vitchutripop T, Srinivasan A, Pantel H, Khanna A, Rakita D. Deep learning approach for critical exposure during division of the inferior mesenteric artery in colorectal surgery. Journal Of Robotic Surgery 2026, 20: 155. PMID: 41486401, DOI: 10.1007/s11701-025-03121-7.Peer-Reviewed Original ResearchArtificial intelligenceDeep learning algorithmsDeep learning approachIntraoperative maneuversColorectal surgeryThree-dimensional mesh modelDetection modelLearning algorithmsVariable operating environmentRobotic-assisted low anterior resectionTwo-dimensional anglesLearning approachLow anterior resectionSurgery videosInferior mesenteric arteryMesh modelRobotic-assisted surgeryVideo
2025
Robotic Approach to Multivisceral Resection for Gastrointestinal Stromal Tumor With En Bloc Resection of the Stomach, Distal Pancreas, and Spleen: A Case Report
Bader J, Liu S, Billingsley K. Robotic Approach to Multivisceral Resection for Gastrointestinal Stromal Tumor With En Bloc Resection of the Stomach, Distal Pancreas, and Spleen: A Case Report. Cureus 2025, 17: e96479. PMID: 41384208, PMCID: PMC12691104, DOI: 10.7759/cureus.96479.Peer-Reviewed Original ResearchGastrointestinal stromal tumorsStromal tumorsInvasion of adjacent organsBloc distal pancreatectomyHigh-risk featuresUncomplicated postoperative recoveryInterdisciplinary tumor boardEn-bloc resectionAdjuvant imatinibMultivisceral resectionSurgical resectionDistal pancreatectomyExtraluminal growthIntraoperative findingsBloc resectionMesenchymal neoplasmsAdjacent organsDistal pancreasCase reportIntraoperative challengesTumor boardPostoperative recoveryPartial gastrectomyResectionRobotic approach
Clinical Trials
Current Trials
A Feasibility Study of Mass-Based Response Drug Screening to Guide Personalized Hyperthermic Intraperitoneal Chemotherapy for High-Grade Appendiceal and Colorectal Adenocarcinoma With Peritoneal Metastasis
IRB ID2000038133RoleSub InvestigatorPrimary Completion Date02/15/2027Recruiting Participants
Academic Achievements & Community Involvement
News
News
- April 27, 2026
Personalized Chemotherapy for Abdominal Cancer: A Q&A with Kiran Turaga
- March 09, 2026
Yale Cancer Center Experts Present Advances in Cancer Research at Major Surgical Meeting
- October 14, 2025
Showcasing the Beauty of Basic Science
- February 05, 2024
Surgical Education Solutions: Grant Recipients Announced
Get In Touch
Contacts
Email